Mallinckrodt PLC (MNK) Shares Bought by Lingohr & Partner Asset Management GmbH

Lingohr & Partner Asset Management GmbH increased its stake in shares of Mallinckrodt PLC (NYSE:MNK) by 152.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,600 shares of the company’s stock after acquiring an additional 20,300 shares during the quarter. Lingohr & Partner Asset Management GmbH’s holdings in Mallinckrodt PLC were worth $1,036,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Ameriprise Financial Inc. increased its stake in Mallinckrodt PLC by 117.3% in the second quarter. Ameriprise Financial Inc. now owns 1,937,444 shares of the company’s stock valued at $86,815,000 after purchasing an additional 1,045,757 shares during the period. Icon Advisers Inc. Co. increased its stake in Mallinckrodt PLC by 165.6% in the second quarter. Icon Advisers Inc. Co. now owns 114,200 shares of the company’s stock valued at $5,117,000 after purchasing an additional 71,200 shares during the period. Alliancebernstein L.P. increased its stake in Mallinckrodt PLC by 15.4% in the second quarter. Alliancebernstein L.P. now owns 3,348,807 shares of the company’s stock valued at $150,060,000 after purchasing an additional 448,011 shares during the period. LSV Asset Management increased its stake in Mallinckrodt PLC by 24.4% in the second quarter. LSV Asset Management now owns 1,249,612 shares of the company’s stock valued at $55,995,000 after purchasing an additional 244,753 shares during the period. Finally, Twin Capital Management Inc. increased its stake in Mallinckrodt PLC by 70.1% in the second quarter. Twin Capital Management Inc. now owns 78,050 shares of the company’s stock valued at $3,497,000 after purchasing an additional 32,170 shares during the period. Hedge funds and other institutional investors own 98.83% of the company’s stock.

Mallinckrodt PLC (MNK) traded down $0.44 during mid-day trading on Monday, reaching $21.76. 5,866,400 shares of the company were exchanged, compared to its average volume of 2,489,536. Mallinckrodt PLC has a 52-week low of $19.00 and a 52-week high of $68.12. The stock has a market capitalization of $2,067.31, a P/E ratio of 2.94, a P/E/G ratio of 0.33 and a beta of 1.46. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08.

Mallinckrodt PLC (NYSE:MNK) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.17. Mallinckrodt PLC had a net margin of 11.43% and a return on equity of 14.79%. The company had revenue of $793.90 million for the quarter, compared to the consensus estimate of $808.93 million. During the same quarter in the prior year, the firm earned $2.04 earnings per share. The company’s revenue for the quarter was down 10.5% compared to the same quarter last year. analysts predict that Mallinckrodt PLC will post 7.23 earnings per share for the current year.

In other Mallinckrodt PLC news, insider Meredith B. Fischer purchased 1,280 shares of Mallinckrodt PLC stock in a transaction on Wednesday, August 30th. The shares were bought at an average price of $39.63 per share, with a total value of $50,726.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.53% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Mallinckrodt PLC (MNK) Shares Bought by Lingohr & Partner Asset Management GmbH” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/11/13/mallinckrodt-plc-mnk-shares-bought-by-lingohr-partner-asset-management-gmbh.html.

A number of research firms have commented on MNK. Oppenheimer Holdings, Inc. set a $70.00 price objective on shares of Mallinckrodt PLC and gave the company a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research upgraded shares of Mallinckrodt PLC from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. BMO Capital Markets restated a “buy” rating and issued a $69.00 price objective on shares of Mallinckrodt PLC in a research note on Friday, July 28th. Piper Jaffray Companies set a $85.00 price objective on shares of Mallinckrodt PLC and gave the company a “buy” rating in a research note on Sunday, July 16th. Finally, Canaccord Genuity set a $87.00 price objective on shares of Mallinckrodt PLC and gave the company a “buy” rating in a research note on Monday, July 17th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $50.44.

About Mallinckrodt PLC

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.

Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).

Institutional Ownership by Quarter for Mallinckrodt PLC (NYSE:MNK)

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply